

PRODUCT DESCRIPTION

Cephalinex® is a lyophilized preparation of rabbit brain cephalin and particulate (microsilica) activator. Cephalinex supplies the platelet phospholipid substitute and negatively charged surface required for plasma coagulation to occur by way of the intrinsic hemostatic pathway.

INTENDED USE

Cephalinex is for use in performing a silica activated partial thromboplastin time (APTT) and coagulation factor assays which are based on a modified APTT.

The APTT is the most widely used method for monitoring intravenous heparin anticoagulation therapy.^{1,2} It is also a fundamental screening test for deficiencies or abnormalities of the intrinsic coagulation factors: VIII, IX, XI, XII, and factors common to both the intrinsic and extrinsic pathways: I (fibrinogen), II, V, X.³ When used in conjunction with a deficient substrate plasma, the APTT provides the basis for the quantitation of specific coagulation factor activities.

PRINCIPLE

The intrinsic capability of blood to form a fibrin clot requires coagulation factors XII (Hageman), XI (plasma thromboplastin antecedent), IX (Christmas), VIII (anti-hemophilic), X (Stuart-Prower), V (proaccelerin), II (prothrombin), I (fibrinogen), platelet phospholipid, and calcium.⁴

Historically, intrinsic coagulation was measured by timing fibrin clot formation upon the recalcification of citrated, anti-coagulated, platelet rich plasma. Measurement with platelet rich plasma, however, relied on the platelets as a source of phospholipid. Variables such as centrifugation and patient platelet count had significant bearing on the test results.⁵

The partial thromboplastin time (PTT), which is a modification of the plasma recalcification time, introduces a platelet substitute which eliminates test variability due to the availability of platelet phospholipid. By adding a substance to activate factors XII and XI, the contact factors, the partial thromboplastin time becomes the activated partial thromboplastin time (APTT). Because coagulation endpoints are shorter and sharper than with the PTT, the APTT has proven to be a simple and highly reliable measurement of the intrinsic coagulation mechanism.⁵

PRECAUTIONS

Cephalinex is FOR IN VITRO DIAGNOSTIC USE ONLY and is NOT FOR INGESTION OR INJECTION.

MATERIALS PROVIDED

Cephalinex, 20 x 3.0mL Store at 2° - 8°C prior to reconstitution.

MATERIALS REQUIRED BUT NOT PROVIDED

1. Purified water, pH 5.3 - 7.2 (distilled, deionized or reagent grade)
2. Pipettes (3.0mL and 0.1mL volume capacities)
3. Citrated control plasmas
4. Calcium Chloride, 0.025M

INSTRUMENTATION

Activated partial thromboplastin time endpoints may be detected by manual or with most optical coagulation analyzers. Follow the manufacturer's instructions for operating the analyzer in use.

COLLECTION AND PREPARATION OF TEST PLASMA^{9, 13}

Test plasma for the APTT should be prepared from 0.11M citrated whole blood.

1. Blood collection
Blood collection for the APTT, as for any coagulation test, should be performed with care to avoid hemolysis or contamination by tissue fluids.
 - a. Evacuated specimen collection tube technique:
Draw blood using tubes containing 0.11M sodium citrate anticoagulant. Invert gently 5 times to mix.
 - b. Syringe Technique:
Draw blood. Mix immediately with 0.11 M sodium citrate by adding 9 parts whole blood to 1 part anticoagulant. Invert gently 5 times to mix.

2. Centrifuge blood at 2500 x g for 15 minutes.
3. Remove platelet poor or platelet free plasma from cells, being careful not to disturb the buffy coat. Plasma should be free of red blood cells and platelets.
4. If testing is delayed, refrigerate the plasma at 2° - 8°C for a maximum of 2 hours.

NOTE: THE FIRST TUBE DRAWN SHOULD NEVER BE USED FOR COAGULATION TESTS

RECONSTITUTION

Warm vial to room temperature prior to reconstitution.

1. Tap the vial to dislodge material adhering to the stopper.
2. Remove the aluminum seal.
3. Remove the stopper and reconstitute the vial contents with the volume of purified water specified.
4. Replace the stopper and invert the vial to thoroughly disperse the contents. Let stand for no less than 15 minutes prior to use to assure complete rehydration of the contents.

Once reconstituted, Cephalinex is stable for seven days when stored in the tightly capped original container at 2° - 8°C.

TEST PROCEDURE

NOTE: FOR BEST RESULTS SUSPENSION OF THE REAGENT SHOULD BE MAINTAINED BY MAGNETIC STIRRING OR INVERSION IMMEDIATELY PRIOR TO USE.

NOTE: FOLLOW THE INSTRUCTIONS IN THE OPERATOR'S MANUAL PROVIDED WITH THE INSTRUMENT IN USE.

QUALITY CONTROL

The precision and accuracy of APTT test results may be affected by a number of factors. Significant interlaboratory differences arise from the variety of coagulation systems used to measure clotting endpoints.^{6,7} Intralaboratory variables which may impact APTT results include: pH of purified water used for reagent reconstitution, pipetting technique, incubation temperatures, incubation time, reagent contamination, and change in reagent lot number.⁸ Periodic quality control procedures, performed on a regular basis, will help to identify the occurrence of any deviations which may lead to erroneous test results.

Each laboratory should establish acceptance limits for each lot of control plasma and APTT reagents, in accordance with established laboratory procedures.⁸

RESULTS

The APTT result is reported as the clotting time endpoint in seconds. In addition to the clotting time, a predetermined normal range should be reported as APTT ranges may vary substantially from laboratory to laboratory.⁷⁻¹⁰

NOTE: Results should correlate within ± five percent (5%).

EXPECTED VALUES

The results obtained with Cephalinex are influenced by the method of coagulation endpoint detection. In general, expected results for APTTs performed with Cephalinex on a photo optical coagulation analyzer will be in the range of 26 to 38 seconds. Each laboratory should establish its own reference range. For manual methods, expected results range from 30 to 42 seconds. Due to this variability, it is essential that each laboratory determine the reference range based on the coagulation analyzer to be used and the patient population to be assessed.

When Cephalinex is used to evaluate the integrity of the intrinsic coagulation mechanism, results outside of the reference range could be indicative of single or multiple factor deficiencies in the intrinsic coagulation pathway or the presence of a circulating inhibitor.

When Cephalinex is used for monitoring heparin therapy, results should be evaluated based on the therapeutic range established by the institution.

LIMITATIONS

Grossly lipemic or hemolyzed specimens may produce erroneous test results. Incorrect blood to anticoagulant ratios may result in spurious test results. The quantity of sodium citrate added to blood must be proportionally decreased in patients with hematocrit values above 53 and increased in patients with hematocrit values below 25.¹¹

NOTE: Delay in testing, difficulty in specimen collection, or venipuncture above the site of a heparin lock may result in a falsely prolonged APTT value. When results are not within the expected limits the possibility of improper specimen collection or handling should be investigated.⁹

PERFORMANCE CHARACTERISTICS

Cephalinex has been tested with photo optical endpoint detection systems. Its precision and sensitivity are sufficient to provide a reliable method of evaluating mild to severe abnormalities in intrinsic coagulation as well as monitoring anticoagulation with heparin.¹²

REFERENCES

1. Cole E, Hall ER, Wu KK: Principles of antithrombotic therapy. In Wu KK: Thromboembolic disorders, pg 91, PSG Publishing Company, Inc., Littleton, 1984.
2. Triplett DA: Heparin: Clinical use and laboratory monitoring. In Triplett DA: Laboratory evaluation of coagulation, pg 272, ASCP Press, Chicago, 1982.
3. Mannucci PM: A multicenter evaluation of partial thromboplastin time reagents in the detection of mild hemophiliacs. In Triplett DA Standardization of coagulation assays: an overview, pg 166, College of American Pathologists, Skokie, 1982
4. Hougie C: The biochemistry of blood coagulation. In Triplett DA: Laboratory evaluation of coagulation, pg 2, American Society of Clinical Pathologists Press, Chicago, 1982.
5. Owen CA, Bowie EJW, Thomson JH: The diagnosis of bleeding disorders, pg 110, Little Brown and Company, Boston, 1975.
6. Poller L: Standardization of the APTT test. Current Status. Scand J Haematol. 25(Suppl 37): 49, 1980.
7. Sabo MG: Coagulation instrumentation and reagent systems. In Triplett DA: Laboratory evaluation of coagulation, pg 330, American Society of Clinical Pathologist Press, 1982.
8. Westgard JO, Barry PL, Hunt MR, Groth T: A multi-rule Shewhart chart for quality control in clinical chemistry Clin Chem. 27(3), 493-501, 1981.
9. Triplett DA, Harms CS: Procedures for the coagulation laboratory, pg 7, American Society of Clinical Pathologists Press, Chicago, 1981.
10. Refsum N, Collen D, Godal HC, Janson T, Mannucci PM, Nilsson IN, Gilhuus-Moe CC: Sensitivity and precision of activated partial thromboplastin time (APTT) methods. Scand J Haematol, 20:89, 1978.
11. Harker LA: Hemostasis manual. F.A. Davis Company, Philadelphia, pg 62, 1974.
12. Ratnoff OD, Forbes CD (eds): Disorders of Hemostasis, W.B. Saunders Co. 2nd ed, Philadelphia, 1991.
13. Clinical and Laboratory Standards Institute (CLSI). Collection, Transport, and Processing of Blood Specimens for Testing Plasma Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline -- Fifth Edition. CLSI document H21-A5 (ISBN 1-56238-657-3). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA. 2008

For a complete list of available products please go to our web site www.biodatacorp.com or contact customer service.

THIS PRODUCT IS WARRANTED TO PERFORM AS DESCRIBED IN THE LABELING AND IN THE LITERATURE OF BIO/DATA CORPORATION AND BIO/DATA CORPORATION DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY OTHER PURPOSE AND IN NO EVENT SHALL BIO/DATA CORPORATION BE LIABLE FOR ANY CONSEQUENTIAL DAMAGES ARISING OUT OF AFORESAID EXPRESSED WARRANTY.



155 Gibraltar Road, Horsham, PA 19044 U.S.A.
(800) 257-3282 U.S.A. (215) 441-4000 Worldwide
(215) 443-8820 Fax Worldwide
customer.service@biodatacorp.com
www.biodatacorp.com

An ISO 13485 Registered Company